Overall survival probability for patients with advanced ovarian cancer following response to first-line chemotherapy
A tool to prognosticate overall survival outcomes in patients with newly diagnosed ovarian cancer about to commence with maintenance olaparib and bevacizumab or bevacizumab monotherapy
Disclaimer & Privacy
The NHMRC Clinical Trials Centre (CTC) strives to keep information stored in this tool up to date, but does not guarantee the accuracy, reliability or currency of the information. Any errors in the information that are brought to our attention will be corrected as soon as possible. The CTC reserves the right to change at any time without notice any information stored in this tool.